Hopp til hovedinnhold
Cushing syndrom: Ved cushings syndrom er det en overproduksjon av kortisol (Bildet viser molekylet kortisol).
Cushing syndrom: Ved cushings syndrom er det en overproduksjon av kortisol (Bildet viser molekylet kortisol).

Cushings syndrom

Cushings syndrom er en sykdom som skyldes overproduksjon av hormonet kortisol, og som fører til omfattende endringer i kroppen. Symptomene er varierte, men økt matlyst, såkalt måneansikt, økt hårvekst, og blåflekker er mulige symptomer.

Sist revidert:
QR
Del pasientinformasjon

Den ligger åpent tilgjengelig på NHI.no sammen annen relevant informasjon

https://nhi.no/sykdommer/barn/hormonsykdommer/cushings-syndrom/ 

Hva er Cushings syndrom?

Årsaker

Symptomer

Diagnostikk

Behandling

Prognose

Å leve med Cushings syndrom

Vil du vite mer?

Kilder

Referanser

Dette dokumentet er basert på det profesjonelle dokumentet Cushings syndrom. Referanselisten for dette dokumentet vises nedenfor.

  1. Evang JA, Carlsen SM, Svartberg J, et al. Endogent Cushings syndrom. Tidsskr Nor Lægeforen 2006; 126: 599-602. PubMed 
  2. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006; 367: 1605-17. PubMed 
  3. Carroll T, Findling JW. Cushing's syndrome. BestPractice, last updated Aug 01, 2013 .
  4. Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet 2015; 386: 913-27. doi:10.1016/ S0140-6736(14)61375-1
  5. Voelker R. New Therapy Offers Direct Cortisol Control for Cushing Disease. JAMA 2020; 323: 1436. doi:10.1001/jama.2020.5157 DOI 
  6. Kjellbom A, Lindgren O, Puvaneswaralingam S, et al. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas A Cohort Study. Ann Intern Med 2021. pmid:34029490 PubMed 
  7. Evang JA, Olsen AL. Cushings syndrom, primær utredning. Nasjonal veileder i endokrinologi. Sist oppdatert 10.03.2019. Siden lest 21.04.2020 www.endokrinologi.no 
  8. Newell-Price J, Trainer P, Besser M et al. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647-72. PubMed 
  9. Boscaro M, Barzon L, Fallo F et al. Cushing's syndrome. The Lancet 2001; 357: 783-91. The Lancet 
  10. Katayama M, Nomura K, Ujihara M et al. Age-dependent decline in cortisol levels and clinical manifestations in patients with ACTH-independent Cushing's syndrome. Clin Endocrinol (Oxf) 1998; 49: 311-6. PubMed 
  11. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD et al. Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 1998; 83: 3083-8. PubMed 
  12. Kaltsas GA, Korbonits M, Isidori AM et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? Clin Endocrinol (Oxf) 2000; 53: 493-500. PubMed 
  13. Kelly WF. Psychiatric aspects of Cushing's syndrome. QJM 1996; 89: 543-51. PubMed 
  14. Nieman LK. Cushing's syndrome: update on signs, symptoms and biochemical screening. Eur J Endocrinol. 2015 Oct;173(4):M33-8. doi: 10.1530/EJE-15-0464 DOI 
  15. Mengden T, Hubmann P, Muller J et al. Urinary free cortisol versus 17-hydroxycorticosteroids: a comparative study of their diagnostic value in Cushing's syndrome. Clin Investig 1992; 70: 545-8. PubMed 
  16. Invitti C, Giraldi FP, de Martin M et al. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. J Clin Endocrinol Metab 1999; 84: 440-8. PubMed 
  17. Yaneva M, Mosnier-Pudar H, Dugue MA et al. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 2004; 89: 3345-51. PubMed 
  18. Putignano P, Toja P, Dubini A et al. Midnight salivary cortisol versus urinary free and midnight serum cortisol as screening tests for Cushing"s syndrome. J Clin Endocrinol Metab 2003; 88: 4153-7. PubMed 
  19. Findling JW, Raff H, Aron DC. The low-dose dexamethasone suppression test: A reevaluation in patients with Cushing's syndrome. J Clin Endocrinol Metab 2004; 89: 1222-6. PubMed 
  20. Papanicolaou DA, Yanovski JA, Cutler GB jr. et al. A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states. J Clin Endocrinol Metab 1998; 83: 1163-7. PubMed 
  21. Yanovski JA, Cutler GB jr., Chrousos GP et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test differentiates mild Cushing's disease from normal physiology. J Clin Endocrinol Metab 1998; 83: 348-52. PubMed 
  22. Jing Y, Hu J, Luo R, et al. Prevalence and Characteristics of Adrenal Tumors in an Unselected Screening Population A Cross-Sectional Study. Ann Intern Med 2022. pmid:36095315 PubMed 
  23. Haug E. Spyttprøver til kortisolmåling. Tidsskr Nor Lægeforen 2007; 127: 718. Tidsskrift for Den norske legeforening 
  24. Løvås K, Husebye ES. Kortisol i spytt ved sykdom i binyrene Tidsskr Nor Lægeforen 2007; 127: 730-2. PubMed 
  25. Pasquali R, Ambrosi B, Armanini D et al. Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. J Clin Endocrinol Metab 2002; 87: 166-75. PubMed 
  26. Hall WA, Luciano MG, Doppman JL et al. Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population. Ann Intern Med 1994; 120: 817-20. Annals of Internal Medicine 
  27. Nieman LK, Biller BMK, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015; 100: 2807-31. pmid:26222757 PubMed